Klacid Dosage/Direction for Use

Film-coated tablet: Patients with respiratory tract/skin and soft tissue infections: Adults: The usual dose is 250 mg twice daily although this may be increased to 500 mg twice daily in severe infections. The usual duration of treatment is 6 to 14 days.
Children older than 12 years: As for adults.
Children younger than 12 years: Use of Klacid Tab 250 mg are not recommended for children younger than 12 years. Clinical trials have been conducted using clarithromycin paediatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin paediatric suspension (granules for oral suspension).
Clarithromycin may be given without regard to meals as food does not affect the extent of bioavailability.
Eradication of H. pylori in patients with duodenal ulcers (Adults): The usual duration of treatment is 6 to 14 days.
Triple Therapy: Clarithromycin (500 mg) twice daily and lansoprazole 30 mg twice daily should be given with amoxycillin 1000 mg twice daily.
Triple Therapy: Clarithromycin (500 mg) twice daily and lansoprazole 30 mg twice daily should be given with metronidazole 400 mg twice daily.
Triple Therapy: Clarithromycin (500 mg) twice daily and omeprazole 40 mg daily should be given with amoxycillin 1000 mg twice daily or metronidazole 400 mg twice daily.
Triple Therapy: Clarithromycin (500 mg) twice daily and omeprazole 20 mg daily should be given with amoxycillin 1000 mg twice daily.
Elderly: As for adults.
Renal impairment: In patients with renal impairment with creatinine clearance less than 30 mL/min, the dosage of clarithromycin should be reduced by one-half, i.e. 250 mg once daily, or 250 mg twice daily in more severe infections. Treatment should not be continued beyond 14 days in these patients.
Modified-release tablet: Adults: The usual recommended dosage of Klacid MR tablet in adults 12 years of age or older is 500 mg once-daily with food.
In more severe infections, the dosage may be increased to 1000 mg once-daily (2 x 500 mg). The usual duration of therapy is 5 to 14 days, excluding treatment of community acquired pneumonia and sinusitis which require 6 to 14 days therapy.
Do not crush or chew Klacid MR tablet.
Pediatric: The use of Klacid MR tablet has not been studied in children less than 12 years of age.
Patients with renal impairment: In patients with severe renal impairment (creatinine clearance less than 30 mL/min), the usual recommended dose is 250 mg once daily. Because the modified-release tablet cannot be split, instead immediate-release tablets should be used. In more severe infections, the recommended dose is one 500 mg modified-release tablet once daily.
No dose adjustment is required for patients with moderate renal impairment (creatinine clearance 30 to 60 ml/min).
The usual duration of treatment is 6 to 14 days. Treatment should not be continued beyond 14 days in these patients.
Patients with impaired hepatic function: Clarithromycin is eliminated mainly via the liver. Patients with severely impaired hepatic function should not be treated with Klacid MR tablets until further clinical experience is available.
Patients treated concomitantly with ritonavir and with: A normal renal function: Dose reduction is not required in patients with normal renal function. However, the daily dose of 1000 mg clarithromycin (equivalent to 2 Klacid MR tablets) should not be exceeded.
Limited renal function (creatinine clearance 30 to 60 ml/min): In patients with a creatinine clearance of 30 to 60 ml/min who are taking Ritonavir concomitantly, the dose level of clarithromycin should be reduced by 50% so that a maximum daily dose of 500 mg clarithromycin (equivalent to 1 Klacid MR tablet) is not exceeded.
Severely impaired renal function (creatinine clearance <30 ml/min): No appropriate dose reduction is feasible in patients with a clearance <30 ml/min who are taking ritonavir concomitantly*.
*Klacid MR tablets cannot be divided. If a dose is reduced to less than 500 mg clarithromycin, other pharmaceutical forms with a lower active substance content are available for these patients.
Elderly patients: Follow the adult dosing instruction if no serious renal impairment is apparent (creatinine clearance <30 ml/min).
Children: Klacid MR has not been tested in patients under 12 years.
Children under 12 years: this medicinal product is not recommended for children under 12 years. An oral suspension of clarithromycin should be used for administration in children.
Children over 12 years: as for adults.
Method of administration: Klacid MR tablets must be taken at the same time every day. The medicinal product should be taken with food and sufficient fluid intake, e.g. a glass of water.
Granules for oral suspension: Pediatric Patients under 12 years of age: Clinical trials have been conducted using Klacid Granules for Oral Susp 125 mg/5 ml in children 6 months to 12 years of age. Therefore, children under 12 years of age should use Klacid Granules for Oral Susp 125 mg/5 ml.
Recommended doses and dosage schedules: The usual duration of treatment is for 5 to 10 days depending on the pathogen involved and the severity of the condition. The recommended daily dosage of Klacid Granules for Oral Susp 125 mg/5 ml in children is given in the following table and is based on a 7.5 mg/kg b.i.d. dosing regime up to a maximum dose of 500 mg b.i.d. The prepared suspension can be taken with or without meals and can be taken with milk.
Klacid Granules for Oral Susp 125 mg/5 ml Dosage in Children: See Table 5.

Click on icon to see table/diagram/image

Renal impairment: In children with creatinine clearance less than 30 ml/min/1.73 m², the dosage of clarithromycin should be reduced by half to 7.5 mg/kg per day.
Dosage should not be continued beyond 14 days in these patients.
Preparation for use: see Special precautions for disposal and other handling under Cautions for Usage.